Clinical trial
Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine…
NCT00379977 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00379977 |
|---|---|
| Title | Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age |
| Official title | Open, Primary Vaccination Study to Assess Safety and Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Administered to Healthy Chinese Infants at 3, 4 and 5 Months of Age. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Tetanus, Haemophilus Influenzae Type b, Acellular Pertussis, Diphtheria |
| Intervention type | Biological |
| Interventions | diphtheria, tetanus, pertussis & Hib vaccine |
| Enrollment | 30 |
| Start date | Sep 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Sep 25, 2006 |
| Last update posted | Oct 12, 2016 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: